SCHEMBL5700236

SCHEMBL5700236

CS(=O)(=O)c1ccnc(C(=O)Oc2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
KDM4E B2RXH2 2/20 0.45
POLB P06746 1/20 0.45
ALDH1A1 P00352 5/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.39
TMPRSS15 P98073 1/20 0.39
NSD2 O96028 1/20 0.39
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALKBH2 Q6NS38 1/20 0.37
ALKBH5 Q6P6C2 1/20 0.37
FTO Q9C0B1 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20791437 0.80 ALDH1A1 (0.50) MAPTKDM4EALDH1A1L3MBTL1HPGD
SCHEMBL20790368 0.78 KDM4E (0.53) MAPTKDM4EALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL30525023 0.78 KDM4E (0.53) MAPTKDM4EALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL6742993 0.78 KMT2A (0.53) ALDH1A1GAAMEN1KMT2AALKBH2
SCHEMBL69530 0.77 MAPT (0.60) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL5700035 0.76 MAPT (0.48) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL5700542 0.76 ALDH1A1 (0.59) MAPTKDM4EPOLBALDH1A1GAA
SCHEMBL5700381 0.76 MAPT (0.48) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL5700255 0.75 ALDH1A1 (0.46) MAPTKDM4EALDH1A1SMN1; SMN2ALKBH2
SCHEMBL28196130 0.75 MAPT (0.47) MAPTKDM4EPOLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270582-B1 TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES MITSUBISHI RAYON CO (JP) 2006-08-30 EP disclosed
US-6693210-B2 USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS MITSUBISHI RAYON CO., LTD. (JP) 2004-02-17 US disclosed
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts MITSUBISHI RAYON CO., LTD. (JP) 2003-04-03 US disclosed
EP-1270582-A1 TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE Mitsubishi Rayon Co., Ltd. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts PDCD1LG2, PIK3CA, PDCD1 MAPT 4407/4885KDM4E 2983/4885POLB 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.